

SGLT2 inhibition – a new therapeutic approach to the management of Type 2 diabetes mellitus (T2DM)

Tuesday 6 December, 18.00–20.00

Room: Sheikh Maktoum A

A CME accredited educational programme organised by Umeå University Hospital on the occasion of the World Diabetes Congress, 2011

Course Director: Prof. Tommy Olsson, Umeå, Sweden

Chairpersons: Prof. Clifford Bailey, Birmingham, UK and Prof. Ele Ferrannini, Pisa, Italy

18:00-18:30 The need to treat glucotoxicity

*Ele Ferrannini
University of Pisa, Italy*

18:30–19:00 SGLT2 inhibition: new concept, new reality?

*Clifford Bailey
Aston University, UK*

19:00–19:30 SGLT2 inhibitors across the T2DM spectrum: earlier disease

*Krzysztof Strojek
Silesian Medical University, Poland*

19:30–20:00 SGLT2 inhibitors across the T2DM spectrum: later disease

*John Wilding
University Hospital Aintree, UK*



This educational programme is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) for up to 2 hours of European external CME credits. Each participant should claim only those hours of credit that have actually been spent in the educational activity. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

This programme is supported by an unrestricted educational grant from Bristol-Myers Squibb and AstraZeneca